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Abstract
Introduction: Nimesulide is a potent anti-inflammatory 
with rapid and long-lasting effects, but also with a high risk 
of hepatotoxicity. Objective: This work aimed to prevent 
nimesulide-induced hepatotoxicity through the association 
of nimesulide with a hepatoprotective agent. Materials and 
Methods: First, we tested three hepatoprotective agents: 
N-acetylcysteine, L-carnitine, and Gingko biloba extract in 
an in vitro hepatic cell model.  Both N-acetylcysteine and G. 
biloba showed promisor results. We selected N-acetylcysteine 
to continue the studies in an animal model. In vivo study was 
performed using male Wistar rats divided in 4 groups: control, 
nimesulide (100mg/kg/day), nimesulide (100mg/kg/day) + 
N-acetylcysteine (100mg/kg/day) and N-acetylcysteine alone 
(100mg/kg/day). Treatments were given by gavage, daily, for 
15 days. Results: Animals receiving nimesulide alone showed 
lower body weight gain compared to control. Body weight 
gain in the nimesulide + N-acetylcysteine group was higher 
than nimesulide alone, evidencing lower toxicity. However, 
the body weight gain of the nimesulide + N-acetylcysteine 
group was still lower than the control animals. Animals treated 
with nimesulide alone presented an increased relative mass of 
heart, liver, and spleen and significant hepatic damage seen in 
microscopy when compared to other groups. N-acetylcysteine 
co-administered with nimesulide prevented the increased 
heart mass, but the same was not true with liver and spleen. 
Conclusions: This work evidence partial protection elicited 
by the association of N-acetylcysteine and nimesulide against 
nimesulide-induced hepatotoxicity.
Keywords: Nimesulide; N-acetylcysteine; Safety; Hepato-
toxicity; Anti-inflammatory.
Resumo
N-acetilcisteína + nimesulida: Estratégia de asso-
ciação com o objetivo de prevenir a hepatotoxici-
dade induzida por nimesulida
Introdução: A nimesulida é um potente anti-inflamatório 
com efeitos rápidos e duradouros, mas também com alto 
risco de hepatotoxicidade. Objetivo: Este trabalho teve 
como objetivo prevenir a hepatotoxicidade induzida pela 
nimesulida por meio da associação de nimesulida a um he-
patoprotetor. Materiais e Métodos: Primeiro, testamos três 
possíveis hepatoprotetores: N-acetilcisteína, L-carnitina e 
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extrato de Gingko biloba em um modelo de células hepáti-
cas in vitro. N-acetilcisteína e G. biloba apresentaram bom 
potencial hepatoprotetor. Selecionamos a N-acetilcisteína 
para continuar os estudos em um modelo animal. O estudo 
in vivo foi realizado com ratos Wistar machos divididos em 
4 grupos: controle, nimesulida (100 mg/kg/dia), nimesulida 
(100 mg/kg/dia) + N-acetilcisteína (100 mg/kg/dia) e N-ace-
tilcisteína isolada (100 mg/kg/dia). Os tratamentos foram 
realizados por gavagem, diariamente, por 15 dias. Resultados: 
Os animais que receberam nimesulida isoladamente apre-
sentaram menor ganho de peso corporal em comparação 
ao controle. O ganho de peso corporal no grupo nimesuli-
da + N-acetilcisteína foi maior que o nimesulida isolado, 
evidenciando menor toxicidade. No entanto, o ganho de 
peso corporal do grupo nimesulida + N-acetilcisteína ainda 
era menor do que os animais controle. Os animais tratados 
com nimesulida isoladamente apresentaram aumento da 
massa relativa do coração, fígado e baço e dano hepático 
significativo observado na microscopia quando compara-
dos a outros grupos. A N-acetilcisteína co-administrada com 
nimesulida impediu o aumento da massa cardíaca, mas tal 
fato não ocorreu com o fígado e o baço. Conclusões: Este tra-
balho evidencia proteção parcial provocada pela associação 
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) 
reduces inflammation, pain, and fever processes by 
decreasing the synthesis of prostaglandins by blocking 
cyclooxygenases.1, 2 Nimesulide is a NSAID marketed 
for the first time in Italy, in 1985, and now it is present 
in more than 50 countries. In some joint diseases such 
as osteoarthritis and arthrosis nimesulide is a more 
effective alternative than other NSAIDs because it 
presents faster and long-lasting analgesic effect.3, 4
Easy access to NSAIDs contributes to the occurrence 
of adverse effects related to these drugs.1, 5, 6 NSAIDs, 
along with antibiotics, are the most common cause 
of drug-induced hepatotoxicity, being responsible 
for about 10% of the cases.7 Clinical manifestations of 
NSAIDs- induced hepatotoxicity vary between low 
aminotransferase increases until fulminant hepatitis 
with a high mortality rate.8
The World Health Organization registered more 
than 320 cases of nimesulide-induced hepatotoxicity 
a year. These hepatic disturbances related to 
nimesulide raise concern about its safety profile. 
In 2002, the Spanish Agency for Medicines and 
Health Products suspended nimesulide due to high 
hepatotoxic risks. Ten years later, the European 
Medicine Agency declared that nimesulide presents a 
higher risk to induce hepatotoxicity when compared 
to other NSAIDs.9 Nimesulide was never approved in 
the USA, United Kingdom, Canada, and New Zeeland.9 
Considering Latin America, Argentina suspended 
nimesulide in all forms of presentation while in 
Brazil is widely prescribed and only contraindicated 
to children under 12 years old because of Reye 
Syndrome risk.9
Mechanisms related to nimesulide-induced 
hepatotoxicity are not fully understood. It might 
involve an increased rate of nimesulide retention in 
the hepatobiliary compartment, adducts formed after 
metabolism that causes cell injury, and the inhibition 
of mitochondrial function with consequent oxidative 
stress and ATP depletion.10, 11
This work aimed to enhance nimesulide safety 
profile through the association with a hepatoprotective 
agent. We tested three different candidates in vitro: 
N-acetylcysteine (potent antioxidant and glutathione 
precursor, well known as an antidote to hepatic 
intoxication related to other drugs),12-14 L-carnitine 
(a mitochondrial function enhancer),15, 16 and Ginkgo 
biloba extract (selected due to its natural antioxidant 
effects).17, 18 After the selection of the best candidate in 
the in vitro challenge, we performed an in vivo study.
de N-acetilcisteína e nimesulida contra hepatotoxicidade 
induzida por nimesulida.
Descritores: Nimesulide; N-acetilcisteína; Segurança; 
Hepatotoxicidade; Anti-inflamatório.
Resumen
N-acetilcisteína + nimesulida: Una estrategia de 
asociación dirigida a prevenir la hepatotoxicidad 
inducida por nimesulida
Introducción: La nimesulida es un potente antiinflamato-
rio con efectos rápidos y duraderos, pero también con un 
alto riesgo de hepatotoxicidad. Objetivo: Este estudio tuvo 
como objetivo prevenir la hepatotoxicidad inducida por 
nimesulida combinando nimesulida con un medicamento 
hepatoprotector. Materiales y métodos: Primero, probamos 
tres candidatos: N-acetilcisteína, L-carnitina y extracto de 
Gingko biloba en un modelo de células hepáticas in vitro. 
N-acetilcisteína y G. biloba mostraron buen potencial. A con-
tinuación, seleccionamos N-acetilcisteína para continuar los 
estudios en un modelo animal. El estudio in vivo se realizó 
con ratas Wistar machos divididas en 4 grupos: control, 
nimesulida (100 mg/kg/día), nimesulida (100 mg/kg/día) + 
N-acetilcisteína (100 mg/kg/día) y N-acetilcisteína aislada 
(100 mg/kg/día). Los tratamientos se realizaron por sonda, 
diariamente, durante 15 días. Resultados: Los animales que 
recibieron nimesulida sola mostraron menos aumento de 
peso corporal en comparación con el control. El aumento de 
peso corporal en el grupo de nimesulida + N-acetilcisteína 
fue mayor que el de nimesulida sola, mostrando menos to-
xicidad. Sin embargo, el aumento de peso corporal del grupo 
nimesulida + N-acetilcisteína fue aún menor que el de los 
animales de control. Los animales tratados con nimesulida 
sola mostraron un aumento en la masa relativa del corazón, 
el hígado y el bazo y un daño hepático significativo obser-
vado al microscopio en comparación con otros grupos. La 
N-acetilcisteína administrada conjuntamente con nimesu-
lida evitó el aumento de la masa cardíaca, pero no sucedió 
lo mismo con el hígado y el bazo. Conclusiones: Este trabajo 
muestra una protección parcial causada por la asociación 
de N-acetilcisteína y nimesulida contra la hepatotoxicidad 
inducida por la nimesulida.
Palabras clave: Nimesulida; N-acetilcisteína; La seguridad; 
Hepatotoxicidad; Antiinflamatorio. 
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Materials and methods
Chemicals
Nimesulide, N-acetylcysteine, L-carnitine, Dulbec-
co’s modified eagle’s medium (DMEM) with phenol 
and 4,500 mg/L glucose, fetal bovine serum (FBS), so-
dium bicarbonate, antibiotic (10,000 U/mL penicillin, 
10,000 µg/mL streptomycin), trypsin, 3-(4,5-dimethyl-
tiazol-2-il)-2,5-diphenyltetrazol bromide (MTT) and 
dimethyl Sulfoxide (DMSO) were purchased from 
Sigma-Aldrich (São Paulo, Brazil), The standardized 
extract of Ginkgo biloba L. (leaves, Ginkgoaceae) was 
obtained from Martins Bauer Group - Finzelberg 
GmbH & Co. KG (Germany), according to the Euro-
pean Pharmacopoeia.
The extract contains between 22 and 27% flavo-
noid glycosides, between 5 and 7% terpenolactones, 
between 2 and 6% bilobalide, between 2.8 and 3.4% 
ginkgolides A, B, C and at most 5 ppm of ginkgolic acids. 
Experimental Design
We aim to prevent nimesulide-induced hepatotox-
icity through the association with a hepatoprotective 
agent. We tested three possible hepatoprotective (N-ace-
tylcysteine, L-carnitine, and Gingko biloba extract) in an 
in vitro hepatic cell model. After the in vitro challenge, 
we selected the most promisor hepatoprotective to 
continue the study in rats. In vivo study was performed 
using male Wistar rats divided into four groups: con-
trol, nimesulide, nimesulide+hepatoprotector (simul-
taneously administered), and hepatoprotective drug 
alone. Treatments were given by gavage, daily, for 15 
days. Hepatotoxicity was monitored during the study. 
Protection was evaluated by the comparison of body 
weight gain, organ relative mass, and liver microscopy 
between groups.
In vitro model: HepG2 cell culture 
The HepG2 cell line is derived from human hepa-
tocyte carcinoma and it has been accepted as a good in 
vitro model to study hepatotoxicity. Cells were gently 
provided by Dr. Marcelo Dutra Arbo, Universidade 
Federal do Rio Grande do Sul (UFRGS), Brazil. Cells 
were cultured in 75 cm2 tissue culture flasks using 
DMEM supplemented with 10% FBS and 1% antibiotic 
solution. Cells were kept in a humidified 5% CO2 - 95% 
air atmosphere, at 37 °C, and the medium was replaced 
every 2-3 days. Cells were subcultured once 70-80% 
confluence was reached.
Cytotoxicity assays
Cells were seeded at a density of 50,000 cells/plate 
in 96-well plates to obtain confluent monolayers in 
24 h. Nimesulide (20 µM, 50 µM, 100 µM, 250 µM, 
500 µM, 1 mM and 2 mM) was incubated for 48 h, 
in 6 replicates of 3 independent experiments.  Con-
centration-response curves were evaluated through 
3-(4,5-dimethyltiazol-2-il)-2,5-diphenyltetrazol bro-
mide (MTT) reduction assay and neutral red uptake 
assay.  Considering cytotoxicity results, we selected 
100 µM nimesulide as the working concentration. 
Nimesulide was co-incubated with N-acetylcysteine 
(25µM, 50µM and 100µM), L-carnitine (100 µM), or 
Gingko biloba extract (25 µM, 50 µM and 100 µM). 
Hepatoprotective concentrations were selected 
following previously described works using hepato-
protective approaches in cell models.14-16, 19
Stock solutions of nimesulide were prepared in 
DMSO. Thus, 0.1% DMSO in culture medium was 
used as vehicle control. All stock solutions were 
stored at -20 °C and freshly diluted on the day of 
the experiment.
MTT reduction assay
Cell viability was assessed through MTT reduction 
assay.20 After the treatment incubation period, cell 
culture medium was removed, and a fresh medium 
containing 0.5 mg/L MTT in HBSS was added and 
incubated for two hours. After the formed formazan 
crystals were dissolved in DMSO, the absorbance was 
measured at 550 nm in a multi-well plate reader. Results 
were graphically presented as the percentage of cell 
death vs. concentration.
Neutral red uptake assay
After the treatment incubation period, the medi-
um was replaced by phosphate buffer saline containing 
50 µg/mL neutral red. Cells were incubated at 37 °C for 
two hours, allowing lysosomes from viable cells to 
uptake the dye.  Cells were gently washed with HBSS 
to eliminate extracellular dye and lysed with 50% 
ethanol in acetic acid solution 1%. Absorbance was 
read at 540 nm in a multi-plate reader. The percent cell 
death relative to that of the control cells was used as 
the cytotoxicity measure.20
In vivo assay
Animals were acclimated for two weeks before the 
study. Food and water were provided ad libitum; animals 
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were subjected to a 12 h light/dark cycle, controlled room 
temperature 22 °C (±3 °C). Experiments were approved by 
the Ethical Committee on the use of animals from the 
University of Passo Fundo (Protocol nº 020/2018).
Adult male Wistar rats (± 300 g, 8 week old) were 
divided into four groups (6 animals/group) and were 
treated by oral gavage, for 15 days. Treatment groups 
were control (saline solution), nimesulide group (100 
mg/kg/day), nimesulide + N-acetylcysteine group (both 
administered at 100 mg/kg/day) and N-acetylcysteine 
group (100 mg/kg/day). 
During the experiment, body mass gain and daily 
clinical evaluations were performed. Systemic toxicity 
was evaluated through the occurrence of piloerection, 
dehydration, bleeding and diarrhea, motor function 
(tone and movement coordination), breathing (rate 
and depth, gasping), mucosal color (pale, cyanotic), 
and clinical signals of abdominal pain.22 Animals 
were euthanized through intraperitoneal injection of 
Ketamine/xylazine (100mg/kg/20mg/kg, respectively).
Biochemical analysis
Blood was collected by cardiac puncture and was 
used to assess serum hepatic biomarkers bilirubin, 
hepatic transaminases (ALT and AST), and gamma-GT, 
using commercial kits.
Organ-target toxicity
Organs (heart, liver, kidneys, and spleen) were 
removed from animals washed with saline solution and 
dried in order to remove residual blood. After macros-
copic evaluation, organs were weighted to assess the 
relative mass (calculated as the percentage of the total 
body weight) as a toxicity parameter.22
Liver microscopy
During necropsy, two fragments from two hepatic 
lobes from all animals were collected and immediately 
kept in a solution containing buffered formalin (10%). 
After fixing, liver pieces were cut and mounted in slides. 
Samples were stained with hematoxylin/eosin and 
analyzed under a light microscope.
Hepatic oxidative stress evaluation
The occurrence of oxidative stress in the liver 
was evaluated in hepatic tissue. Liver samples were 
homogenized [1:4 (m/v)] in ice-cold phosphate-buffered 
saline solution, pH 7.4, with an Ultra-Turrax homogenizer 
and centrifuged (3 000 g, 10 min).22 Aliquots of supernatant 
were taken to assess hepatic protein levels,23 lipid 
peroxidation,24 and non-proteic thiols content.25
Statistical analysis
Results were presented as mean±standard deviation 
from independent experiments. Normality distribution 
was assessed through the Shapiro-Wilk test. Relative 
body mass gain was analyzed through two-way ANOVA. 
Statistical comparisons between groups that presented 
normal distribution were performed by One-Way 
ANOVA followed by Tukey post hoc test (organ relative 
weights and hepatic oxidative stress) and Kruskal-Wallis 
followed by Dunn’s post hoc (biochemical parameters) 




After analyzing the concentration-response curves 
of nimesulide (Figure 1), we selected the concentration 
of 100 µM to further studies. This concentration 
was chosen because it kills cells around 60 % when 
compared to control conditions, as evidenced in 
Figure 1.
Both N-acetylcysteine and Ginkgo biloba extract 
significantly protected cells from nimesulide-induced 
cytotoxicity, as demonstrated by both cytotoxic-
ity assays (Figure 2). L-carnitine did not counteract 
nimesulide damage (Figure 2). Thus, we chose N-ace-
tylcys-teine to continue the study, considering 
significant clinical experience using this drug as an 
antidote to revert hepatotoxicity of other drugs such 
as acetaminophen.12-14
N-acetylcysteine partially protects against ni-
mesulide-induced toxicity 
During in vivo study, control and N-acetylcysteine 
groups increased relative body weight gain similarly, 
evidencing the lack of systemic toxicity. Animals 
receiving nimesulide alone showed lower body 
weight gain compared to control (p<0.0001). Animals 
treated nimesulide + N-acetylcysteine significantly 
increased body weight gain compared to nimesulide 
alone (p<0.05), evidencing lower toxicity obtained 
with this association. However, systemic toxicity was 
not fully antagonized because the body weight gain 
of the nimesulide + N-acetylcysteine group was still 
lower than control animals (p<0.001) (Figure 3).
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Figure 1. Effect of different concentrations of nimesulide after 48 h incubation at 37 °C with HepG2 cells evaluated throu-
gh A) MTT reduction assay and B) Neutral red uptake assay. Results are presented as means (%) ±standard deviation of 3 
independent experiments. Statistical comparison were made using one-way ANOVA test followed by Tukey post hoc test 
(*** p<0.001 vs control)
Figure 2. Citotoxicity results after co-exposure of nimesulide and 3 different hepatoprotectors after 48 h at 37 °C. Results 
are presented as means (%) ±standard deviation of 3 independent experiments. Statistical comparison were made using 
one-way ANOVA test followed by Tukey post hoc test (*** p<0.001 vs control; ### p<0.001 vs nimesulide group)
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Figure 3. Relative body weight gain. Results are presented as mean ± standard deviation. Significant results were seen 
between nimesulide (100mg/kg) and control groups and nimesulide (100mg/kg) and nimesulide (100mg/kg) + N-acetyl-
cysteine (100mg/kg) groups (p<0.05)
Two animals from the nimesulide group died before 
the end of the study (on day 7 and day 9). Necropsy 
revealed hepatic changes such as degeneration, diffuse 
centrilobular necrosis, peritonitis, and tubular necrosis 
on kidneys (Figure 4).
Hepatic microscopic lesions
The typical hepatic lesions seen in nimesulide 
groups were hepatocellular degeneration and necrosis. 
Animals treated with nimesulide alone presented 
more significant hepatic damage than other groups 
and when compared to control. Despite of that, the 
nimesulide + N-acetylcysteine group also showed 
injuries (Figure 4).
Organ-target toxicity
Nimesulide alone caused an increased relative 
mass of heart, liver, and spleen when compared to 
control groups. N-acetylcysteine co-administered 
with nimesulide reverted the increased heart mass 
but failed to revert increased hepatic or spleen mass 
compared to nimesulide alone group (Figure 5). 
Treatments did not cause any change in the relative 
weight of kidneys (data not shown).
Biochemical and oxidative stress results
It was not observed significant differences between 
groups in biochemical biomarkers or oxidative stress 
parameters (hepatic lipid peroxidation, total hepatic 
protein level, and non-protein thiols on the liver) 
(data not shown).
Discussion
The major finding of this work is to evidence that 
N-acetylcysteine partially reverts nimesulide-induced 
hepatotoxicity. We aimed to simulate the hepato-
toxicity observed as an adverse effect obtained in 
therapeutic doses and not in anoverdose context. 
Thus, the selected dose would not be too far from the 
pharmacological dose. Then we extended treatment 
to 15 days. Nimesulide scheme dose regimen was also 
supported by previous studies in rats.21 The N-acetylcys-
teine dose was selected considering hepatoprotective 
results observed in rats when associated with other 
hepato-toxicity drugs.22
N-acetylcysteine was selected as the most promising 
hepatoprotective drug after in vitro studies. Cytotoxicity 
results demonstrate that both N-acetylcysteine and G. 
biloba extract revert cell death obtained with nimesulide 
alone. We invested in N-acetylcysteine to continue 
in vivo studies considering the clinical experience and 
consolidated studies using this antidote in the hepato-
toxicity of other drugs such as acetaminophen.27-30 After 
being absorbed, N-acetylcysteine is biotransformed by 
acetyltransferases to L-cysteine, which is subtract to 
glutathione synthesis. Thus, N-acetylcysteine presents a 
direct free species scavenger effect and also acts as a glu-
tathione precursor, being recognized as a board antioxi-
dant.13, 14, 31 This mechanism may contribute to protective 
results against nimesulide-induced oxidative stress.10, 11
In the in vivo study, N-acetylcysteine partially pro-
tected animals treated with nimesulide, as demonstrated 
v. 19, n. 2, jul-dez/2020        97 
Amanda G. Elias e cols • N-acetilcisteina + Nimesulida
Figure 4. A), B) e C) Liver from nime-
sulide treated rat died on day 7. A) 
Hepatic centrolobullar region showing 
degeneration and necrosisHE, 400X. 
B). Hepatic centrolobullar region 
showing degeneration and hemor-
rhagic necrosis. HE, 200X. C) Kidney, 
córtex, showing degeneration and 
tubular necrosis with hyaline cylinders 
(arrow).HE, 400X. D) and E) Liver from 
nimesulide group presenting D) hepa-
tocellular degeneration and necrosis.
(arrows) HE, 100x. E) HE, 200x. F) 
Liver from nimesulide + N-acetylcys-
teine group presenting hepatocellular 
degeneration and necrosis.(arrows) 
HE, 400x
Figure 5. Relative mass of heart, liver and spleen after in vivo study. Results are presented as mean ± standard deviation  
(N= 6 rats per group). Statistical comparison were made using one-way ANOVA test followed by Tukey post hoc test (* 
p<0.05 vs. control; ** p<0.01 vs. control)
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by the recovery in relative body weight gain observed 
in nimesulide + N-acetylcysteine rats compared to nime-
sulide group. However, co-administration of N-acetyl-
cysteine with nimesulide was not enough to fully revert 
toxicity, considering body weight gain in this group is 
still lower than control animals. The partial protection 
obtained with N-acetylcysteine is also proved in micro-
scopic results since both groups receiving nimesulide 
presented hepatic lesions, but more pronounced when 
nimesulide is given alone.
Increases in the relative mass of livers from the 
nimesulide group are related to hepatocyte commit-
ment showed in microscopy. One hypothesis to in-
creased heart volume observed here is a secondary effect 
to progressive hepatic decompensation. In this scenario, 
blood volume is redistributed, decreasing central circu-
lation, and increasing water retention.32, 33  However, we 
cannot exclude a direct effect since COX-2 inhibitors are 
related to a higher risk of a heart attack.1
Here we did not show changes in biochemical 
biomarkers or hepatic oxidative stress. The absence 
of these expected alterations might be related to an in 
vivo endpoint (15 days). Apparently, 15 days is enough 
for cellular adaptations to restore these transient 
markers. This is a reliable hypothesis considering the 
plasticity/adaptation ability of the liver.34 Moreover, 
similarly to what is observed in nimesulide in humans, 
it seems that hepatotoxicity is strongly dependent of 
individual susceptibility.32 Thus, in our study, two 
rats treated with nimesulide alone died on days 7 and 
9. The other rats, which also presented lower body 
weight gain and apathy, recovered until the end of the 
experiment. Necropsy of animals found dead revealed 
hepatic injury and even renal changes that deserve to 
be highlighted in future approaches. 
G. biloba extract is also an excellent candidate 
to be employed as a hepatoprotective agent against 
nimesulide-induced hepatotoxicity, as suggested by 
our in vitro preliminary study. This extract increases 
prostacyclin synthesis and inhibits oxidative stress 
associated with inflammation.17 Flavonoids and 
terpenes present in this plant are related to antia-
poptotic effects, which might contribute to hepato-
protection.17, 18
L-carnitine does not seem to attenuate nime-
sulide-induced cell damage in our hepatic cell model. 
The mechanism of action of L-carnitine is focused 
on mitochondria.15 L-carnitine and acetyl-L-carni-
tine enhance mitochondrial function because of 
their key-role in β-oxidation and removal of toxic 
substrates from mitochondria.35-37 However, the in-
jury caused by nimesulide involves more complex 
mechanisms.11
To the best of our knowledge, we show for the 
first time, the protection elicited by N-acetylcysteine 
against nimesulide-induced hepatotoxicity. Despite 
the excellent effects of N-acetylcysteine used as an 
antidote in another drug-induced hepatotoxicity, the 
protection obtained here is only partial.
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